AKT regulates NPM dependent ARF localization and p53mut stability in tumors

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6142-6167

  Hamilton, Garth ^a   Abraham, Aswin G ^a   Morton, Jennifer ^b   Sampson, Oliver ^a   Pefani, Dafni E ^a   Khoronenkova, Svetlana ^a   Grawenda, Anna ^a   Papaspyropoulos, Angelos ^a   Jamieson, Nigel ^c   McKay, Colin ^c   Sansom, Owen ^b   Dianov, Grigory L ^a   O'Neill, Eric ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

AKT; ARF; Cancer; p53; Pancreatic

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ARF PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P73; UBIQUITIN PROTEIN LIGASE E3; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GEL ELECTROPHORESIS; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOLECULAR BIOLOGY; MOUSE; MUTANT; NONHUMAN; OLIGOMERIZATION; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SENESCENCE; TUMOR XENOGRAFT; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PANCREAS TUMOR; PHOSPHORYLATION;

ANIMALS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906275106     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2178     Document Type: Article

References (106)

1. Fruman DA, Meyers RE and Cantley LC. Phosphoinositide kinases. Annual review of biochemistry. 1998; 67:481-507.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer. 2009; 9(8):550-562.
3. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews Drug discovery. 2005; 4(12):988-1004.
4. West KA, Castillo SS and Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2002; 5(6):234-248.
5. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer treatment reviews. 2004; 30(2):193-204.
6. Arcaro A and Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Current genomics. 2007; 8(5):271-306.
7. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). International journal of oncology. 2012; 40(3):639-644.
8. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature reviews Drug discovery. 2009; 8(8):627-644.
9. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-1967.
10. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(35):4688-4695.
11. Lowe SW and Lin AW. Apoptosis in cancer. Carcinogenesis. 2000; 21(3):485-495.
12. Vousden KH and Lu X. Live or let die: the cell's response to p53. Nature reviews Cancer. 2002; 2(8):594-604.
13. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. The Journal of clinical investigation. 1999; 104(3):263-269.
14. Oren M. Regulation of the p53 tumor suppressor protein. The Journal of biological chemistry. 1999; 274(51):36031-36034.
15. Fridman JS and Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22(56):9030-9040.
16. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307-310.
17. Kubbutat MH, Jones SN and Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630):299-303.
18. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nature reviews Cancer. 2006; 6(9):663-673.
19. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB and Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-217.
20. Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S and Serrano M. Tumour biology: Policing of oncogene activity by p53. Nature. 2006; 443(7108):159.
21. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G and Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997; 91(5):649-659.
22. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998; 92(6):713-723.
23. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-1238.
24. Brosh R and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature reviews. 2009; 9(10):701-713.
25. Freed-Pastor WA and Prives C. Mutant p53: one name, many proteins. Genes & development. 2012; 26(12):1268-1286.
26. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T and Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011; 71(23):7168-7175.
27. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS and Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes & development. 2008; 22(10):1337-1344.
28. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G and Haupt Y. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a genderdependent manner. Cell Cycle. 2013; 12(11):1722-1731.
29. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119(6):847-860.
30. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK and Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-872.
31. Nagila A, Netsawang J, Srisawat C, Noisakran S, Morchang A, Yasamut U, Puttikhunt C, Kasinrerk W, Malasit P, Yenchitsomanus PT and Limjindaporn T. Role of CD137 signaling in dengue virus-mediated apoptosis. Biochemical and biophysical research communications. 2011; 410(3):428-433.
32. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F and Moll UM. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Molecular cancer research: MCR. 2011; 9(5):577-588.
33. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS and DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & development. 2003; 17(24):3112-3126.
34. Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M and Ronai Z. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. Journal of molecular biology. 2000; 295(4):1009-1021.
35. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-5014.
36. Colombo E, Alcalay M and Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene. 2011; 30(23):2595-2609.
37. Grisendi S, Mecucci C, Falini B and Pandolfi PP. Nucleophosmin and cancer. Nature reviews Cancer. 2006; 6(7):493-505.
38. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, Helin K, Falini B and Pelicci PG. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Molecular and cellular biology. 2005; 25(20):8874-8886.
39. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R and Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell. 2003; 12(5):1151-1164.
40. Kuo ML, den Besten W, Bertwistle D, Roussel MF and Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004; 18(15):1862-1874.
41. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW and Quelle DE. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Molecular and cellular biology. 2005; 25(4):1258-1271.
42. Bertwistle D, Sugimoto M and Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Molecular and cellular biology. 2004; 24(3):985-996.
43. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M and Pelicci PG. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006; 66(6):3044-3050.
44. den Besten W, Kuo ML, Williams RT and Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell cycle (Georgetown, Tex. 2005; 4(11):1593-1598.
45. Lee C, Smith BA, Bandyopadhyay K and Gjerset RA. DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 2005; 65(21):9834-9842.
46. Lin AW and Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(9):5025-5030.
47. Llanos S, Clark PA, Rowe J and Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nature cell biology. 2001; 3(5):445-452.
48. Rodway H, Llanos S, Rowe J and Peters G. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene. 2004; 23(37):6186-6192.
49. Lee SB, Xuan Nguyen TL, Choi JW, Lee KH, Cho SW, Liu Z, Ye K, Bae SS and Ahn JY. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(43):16584-16589.
50. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S and Los M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. Journal of cell science. 2008; 121(Pt 7):979-988.
51. Lee HH, Kim HS, Kang JY, Lee BI, Ha JY, Yoon HJ, Lim SO, Jung G and Suh SW. Crystal structure of human nucleophosmin-core reveals plasticity of the pentamerpentamer interface. Proteins. 2007; 69(3):672-678.
52. Enomoto T, Lindstrom MS, Jin A, Ke H and Zhang Y. Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem. 2006; 281(27):18463-18472.
53. Mitrea DM and Kriwacki RW. Cryptic disorder: an order-disorder transformation regulates the function of nucleophosmin. Pac Symp Biocomput. 2012:152-163.
54. Chan PK and Chan FY. Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochimica et biophysica acta. 1995; 1262(1):37-42.
55. Yu Y, Maggi LB, Jr., Brady SN, Apicelli AJ, Dai MS, Lu H and Weber JD. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Molecular and cellular biology. 2006; 26(10):3798-3809.
56. Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R, Mannucci R, Manes N, Pettirossi V, Pileri SA, Nicoletti I and Falini B. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2009; 23(3):501-509.
57. Chen D, Shan J, Zhu WG, Qin J and Gu W. Transcriptionindependent ARF regulation in oncogenic stress-mediated p53 responses. Nature. 2010; 464(7288):624-627.
58. Mayo LD and Donner DB. A phosphatidylinositol 3-kinase/ Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(20):11598-11603.
59. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature cell biology. 2001; 3(11):973-982.
60. Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L and Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008; 27(30):4210-4220.
61. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell. 2003; 4(6):437-450.
62. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T and Tuveson DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & development. 2001; 15(24):3243-3248.
63. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M and Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature genetics. 2001; 29(4):418-425.
64. Lee JM and Bernstein A. p53 mutations increase resistance to ionizing radiation. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(12):5742-5746.
65. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S and Bernhard EJ. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer research. 2008; 68(14):5915-5923.
66. Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Galanti S, La Rosa F, Floridi A, Bellacosa A, Passananti C, Blandino G and Fanciulli M. Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer cell. 2010; 18(2):122-134.
67. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer cell. 2003; 3(4):403-410.
68. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG and Bernhard EJ. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer research. 2009; 69(15):6347-6354.
69. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR and Sansom OJ. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(1):246-251.
70. Mantoni TS, Lunardi S, Al-Assar O, Masamune A and Brunner TB. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer Res. 2011; 71(10):3453-3458.
71. McCloskey R, Menges C, Friedman A, Patel D and McCance DJ. Human papillomavirus type 16 E6/E7 upregulation of nucleophosmin is important for proliferation and inhibition of differentiation. Journal of virology. 2010; 84(10):5131-5139.
72. Walerych D, Napoli M, Collavin L and Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11):2007-2017.
73. Wang X, Yi L, Zhu Y, Zou J, Hong Y and Zheng W. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERbeta and HER-2 expression. Tumori. 2011; 97(2):185-190.
74. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE and Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PloS one. 2008; 3(8):e3065.
75. Coates AS, Millar EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA and Sutherland RL. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast cancer research: BCR. 2012; 14(6):R143.
76. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nature reviews Cancer. 2011; 11(11):761-774.
77. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ and Adams PD. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 2011; 42(1):36-49.
78. Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y and Yang C. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene. 2009; 28(47):4201-4211.
79. Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature cell biology. 1999; 1(1):20-26.
80. Lohrum MA, Ashcroft M, Kubbutat MH and Vousden KH. Identification of a cryptic nucleolar-localization signal in MDM2. Nature cell biology. 2000; 2(3):179-181.
81. Moulin S, Llanos S, Kim SH and Peters G. Binding to nucleophosmin determines the localization of human and chicken ARF but not its impact on p53. Oncogene. 2008; 27(17):2382-2389.
82. Colombo E, Marine JC, Danovi D, Falini B and Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nature cell biology. 2002; 4(7):529-533.
83. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D and Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer cell. 2004; 5(5):465-475.
84. Fukawa T, Ono M, Matsuo T, Uehara H, Miki T, Nakamura Y, Kanayama HO and Katagiri T. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas. Cancer research. 2012; 72(22):5867-5877.
85. Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD and Pearson RB. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012; 31(15):1949-1962.
86. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C and Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436(7051):725-730.
87. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445(7128):656-660.
88. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI and Martins CP. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010; 468(7323):567-571.
89. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L and Evan GI. Distinct thresholds govern Myc's biological output in vivo. Cancer cell. 2008; 14(6):447-457.
90. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE and Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature cell biology. 2007; 9(5):493-505.
91. Goh AM, Coffill CR and Lane DP. The role of mutant p53 in human cancer. The Journal of pathology. 2011; 223(2):116-126.
92. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ and Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer cell. 2012; 22(6):751-764.
93. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998; 12(19):2984-2991.
94. Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, Burgess DJ, Eischen CM and Murphy ME. The ARF tumor suppressor can promote the progression of some tumors. Cancer research. 2008; 68(23):9608-9613.
95. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M and Pandolfi PP. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Science signaling. 2009; 2(84):ra44.
96. Chen G, Ghosh P, O'Farrell T, Munk R, Rezanka LJ, Sasaki CY and Longo DL. Transforming growth factor beta1 (TGF-beta1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53. The Journal of biological chemistry. 2012; 287(27):23184-23195.
97. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & development. 2012; 26(12):1300-1305.
98. Gajria D and Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy. 2011; 11(2):263-275.
99. Rebucci M, Peixoto P, Dewitte A, Wattez N, De Nuncques MA, Rezvoy N, Vautravers-Dewas C, Buisine MP, Guerin E, Peyrat JP, Lartigau E and Lansiaux A. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. International journal of oncology. 2011; 38(1):189-200.
100. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
101. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK and Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol. 2011; 225(4):479-489.
102. Schreiber E, Matthias P, Muller MM and Schaffner W. Rapid detection of octamer binding proteins with 'miniextracts', prepared from a small number of cells. Nucleic acids research. 1989; 17(15):6419.
103. Woodhouse BC, Dianova, II, Parsons JL and Dianov GL. Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks. DNA repair. 2008; 7(6):932-940.
104. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007; 129(6):1065-1079.
105. Jin L, Feng T, Shih HP, Zerda R, Luo A, Hsu J, Mahdavi A, Sander M, Tirrell DA, Riggs AD and Ku HT. Colonyforming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine/acinar colonies in laminin hydrogel. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(10):3907-3912.
106. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ and Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(13):6665-6670.